MorphoSys AG (NASDAQ:MOR) Q1 2020 Earnings Conference Call - Final Transcript
May 07, 2020 • 08:00 am ET
financial guidance might potentially be impacted by the ongoing global COVID-19 crisis on MorphoSys' business operations including, but not limited to the company's supply chain, clinical trial conduct as well as time lines for regulatory and commercial execution.
With this, I would like to end my part and would like to turn the call back to Jean-Paul for his closing remarks. Thank you.
Let me close by reminding you of our key priorities. Our most important goal is the flawless U.S. launch of tafasitamab, assuming FDA approval. As I have discussed today, we are actively preparing and are confident that we are in excellent shape to launch despite the current circumstances. We have successfully built our commercial organization and hired a strong and experienced team across all functions. We have established a strong partnership with Incyte. And together, we will significantly increase our share of voice to make this launch a success. Beyond the U.S., we anticipate the submission of a European MAA mid this year with a potential launch in Europe in mid-2021. We are joining forces with Incyte for a broad clinical development of tafasitamab beyond r/r DLBCL to explore the full potential of the product.
We are jointly working on optimizing the development plan, and we will provide you an update later this year. In addition to tafasitamab, we will continue to advance our other proprietary programs, and we are actively pursuing in-licensing opportunities to diversify our pipeline. Importantly, we are in a very strong financial position to effectively and fully execute on our strategic plans. In conclusion, I'm very pleased with our accomplishments to date and excited about our future.
I look forward to updating you on our progress.
Thank you, Jens and Jean-Paul. We'd now like to open the call to your questions.